KR20120061041A - ＩＬ?１β 항체 및 이의 결합 단편의 심혈관 관련 용도 - Google Patents

ＩＬ?１β 항체 및 이의 결합 단편의 심혈관 관련 용도 Download PDF

Info

Publication number
KR20120061041A
KR20120061041A KR1020117031198A KR20117031198A KR20120061041A KR 20120061041 A KR20120061041 A KR 20120061041A KR 1020117031198 A KR1020117031198 A KR 1020117031198A KR 20117031198 A KR20117031198 A KR 20117031198A KR 20120061041 A KR20120061041 A KR 20120061041A
Authority
KR
South Korea
Prior art keywords
antibody
binding
subject
fragment
cardiovascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117031198A
Other languages
English (en)
Korean (ko)
Inventor
패트릭 제이 스캐넌
알란 엠 솔링거
제프리 디 펠드스타인
Original Assignee
조마 테크놀로지 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 조마 테크놀로지 리미티드 filed Critical 조마 테크놀로지 리미티드
Publication of KR20120061041A publication Critical patent/KR20120061041A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020117031198A 2009-05-29 2010-05-28 ＩＬ?１β 항체 및 이의 결합 단편의 심혈관 관련 용도 Withdrawn KR20120061041A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18267909P 2009-05-29 2009-05-29
US61/182,679 2009-05-29
US25257109P 2009-10-16 2009-10-16
US61/252,571 2009-10-16
US31300110P 2010-03-11 2010-03-11
US61/313,001 2010-03-11
PCT/US2010/036761 WO2010138939A1 (en) 2009-05-29 2010-05-28 CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF

Publications (1)

Publication Number Publication Date
KR20120061041A true KR20120061041A (ko) 2012-06-12

Family

ID=43223130

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117031198A Withdrawn KR20120061041A (ko) 2009-05-29 2010-05-28 ＩＬ?１β 항체 및 이의 결합 단편의 심혈관 관련 용도

Country Status (15)

Country Link
US (3) US20100316651A1 (enExample)
EP (1) EP2435073A4 (enExample)
JP (2) JP5763625B2 (enExample)
KR (1) KR20120061041A (enExample)
CN (2) CN102573893A (enExample)
AU (1) AU2010253924B2 (enExample)
BR (1) BRPI1011228A2 (enExample)
CA (1) CA2763161A1 (enExample)
EA (1) EA201101643A1 (enExample)
HK (1) HK1245111A1 (enExample)
IL (1) IL216660A0 (enExample)
MX (1) MX2011012666A (enExample)
NZ (1) NZ597024A (enExample)
SG (3) SG2014014534A (enExample)
WO (1) WO2010138939A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2623039C2 (ru) * 2011-04-01 2017-06-21 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Дигидропиридины (клевидипин) кратковременного действия для применения в восстановлении после инсульта
WO2013049278A1 (en) 2011-09-30 2013-04-04 Novartis Ag USE OF IL-1 ß BINDING ANTIBODIES
ES2534782T3 (es) * 2012-02-02 2015-04-28 Baylor College Of Medicine Sistema biológico de administración y expresión basado en adenovirus para uso en el tratamiento de la osteoartritis
CN103588878A (zh) * 2012-08-15 2014-02-19 江苏泰康生物医药有限公司 一种人源化抗人白细胞介素1 β单克隆抗体及其制备与应用
HK1211960A1 (en) * 2012-10-04 2016-06-03 Xbiotech, Inc Treating vascular disease and complications thereof
US10000565B2 (en) 2012-11-16 2018-06-19 Novartis Ag Use of IL-1 β binding antibodies for treating peripheral arterial disease
US10000557B2 (en) * 2012-12-19 2018-06-19 Dnae Group Holdings Limited Methods for raising antibodies
CN103059136A (zh) * 2012-12-24 2013-04-24 浙江大学 抗中华鳖IL-1β多克隆抗体的制备及在检测中的应用
WO2014115022A1 (en) 2013-01-25 2014-07-31 Baylor College Of Medicine A helper-dependent adenoviral gene therapy delivery and expression system
KR102337954B1 (ko) * 2018-08-16 2021-12-10 차의과학대학교 산학협력단 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법
AU2020267329B2 (en) * 2019-05-03 2026-03-26 University Of Zurich Treatment of brain ischemia-reperfusion injury
US20220275079A1 (en) * 2020-11-20 2022-09-01 The General Hospital Corporation Clonal Hematopoiesis and Risk of Chronic Liver Disease
GB202400340D0 (en) 2024-01-10 2024-02-21 Wotherspoon Hugh Robert IL-1B binding antibody

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820383B2 (en) * 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
AR016551A1 (es) * 1997-07-30 2001-07-25 Smithkline Beecham Corp Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US7860583B2 (en) * 2004-08-25 2010-12-28 Carefusion 303, Inc. System and method for dynamically adjusting patient therapy
WO2002076344A1 (en) * 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US20040106954A1 (en) * 2002-11-15 2004-06-03 Whitehurst Todd K. Treatment of congestive heart failure
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
EP2361933A3 (en) * 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
US20060171948A1 (en) * 2005-02-02 2006-08-03 Weinstein Steven P Methods of using IL-1 antagonists to reduce C-reactive protein
WO2006084145A2 (en) * 2005-02-02 2006-08-10 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to reduce c-reactive protein
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
ES2335232T3 (es) * 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
EP1940880A2 (en) * 2005-10-14 2008-07-09 Novo Nordisk A/S Treating diabetes using inhibitors of il-1
JP4524275B2 (ja) * 2006-09-01 2010-08-11 日本ポリプロ株式会社 ビニル基および極性基含有プロピレン系共重合体及びそれを用いる重合体の製造方法。
WO2008077145A2 (en) * 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases

Also Published As

Publication number Publication date
CN102573893A (zh) 2012-07-11
SG2014014534A (en) 2014-07-30
EA201101643A1 (ru) 2012-12-28
EP2435073A1 (en) 2012-04-04
NZ597024A (en) 2014-01-31
EP2435073A4 (en) 2013-03-27
JP2015120704A (ja) 2015-07-02
CA2763161A1 (en) 2010-12-02
BRPI1011228A2 (pt) 2019-09-24
JP2012528796A (ja) 2012-11-15
HK1245111A1 (zh) 2018-08-24
SG176265A1 (en) 2012-01-30
MX2011012666A (es) 2011-12-16
US20180155420A1 (en) 2018-06-07
WO2010138939A1 (en) 2010-12-02
AU2010253924A1 (en) 2012-01-19
US10611832B2 (en) 2020-04-07
CN107243077A (zh) 2017-10-13
IL216660A0 (en) 2012-02-29
US20210009679A1 (en) 2021-01-14
SG10201500180RA (en) 2015-03-30
AU2010253924B2 (en) 2015-01-22
JP5763625B2 (ja) 2015-08-12
US20100316651A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
US10611832B2 (en) Cardiovascular related uses of IL-1β antibodies and binding fragments thereof
DK2391650T3 (en) Methods of treating gout
JP5607613B2 (ja) 関節リウマチの治療のための方法
JP5904645B2 (ja) ＩＬ−１β関連病態の治療のための方法
CA2873914A1 (en) Il-1.beta. binding antibodies and fragments thereof
AU2013203560A1 (en) Cardiovascular related uses of IL-1beta antibodies and binding fragments thereof
AU2015203141A1 (en) Methods for the treatment of gout

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20111227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20140521

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150528

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20151124

WITB Written withdrawal of application